Asieris announced initiation of APL-1202 pivotal clinical trial

On Feb 26th, Asieris hold a successful meeting for initiation of APL-1202 pivotal clinical trial.

APL-1202 is the world’s first oral irreversible metaP2 inhibitor in clinical trials. It has many advantages like novel mechanism of action, superior safety and oral administration, comparing to current intravesical chemotherapy for Non-Muscle Invasive Bladder Cancer (NMIBC). Efficacy in a finished Phase II trial has been widely recognized from patients and doctors.

APL-1202 Pivotal Clinical Trial is led by Professor Ye Dingwei from Shanghai University Cancer Center Hospital and Professor Li Hanzhong from Beijing Union Medical College Hospital and carried out in 35 clinical centers national wide. Around 80 Investigators/clinical agency heads had attended the meeting. Other attendants include Asieris’ clinical research team and the CRO company Tigermed’s project team.

Senior medical director Jasmine Sun from Tigermed hold the meeting. Professor Ye and Professor Li recognized the clinical efficacy of APL-1202 and they were optimistic for the potential efficacy in pivotal trial. They regarded APL-1202 as a disruptive innovation for Non-Musule-Invasive Bladder Cancer (NMIBC) and looked forward to having this new treatment available for the patients as soon as possible.

APL-1202 pivotal trial is a multicenter, double-blind, placebo-controlled trial in China evaluating APL-1202 in combination with intravesical chemotherapy for the treatment of patients with intermediate- or high-risk NMIBC relapsed from chemotherapies. Project manager from Tigermed briefed the protocol and many investigators gave great suggestions.  A team composed by investigators form Phase II including Professor Ye and Professor Li gave detailed answers for questions on site and thanks for all support to ensure smooth progress of such pivotal trial.

Professor Ye and Dr. Kevin Pan (CEO of Asieris) made concluding speeches. They thanked all investigators for their highly professional participation and hoped to work with more than 30 centers to complete the clinical trial and successfully launch APL-1202.